scholarly journals A HIGHLY BIOAVAILABLE OMEGA-3 FREE-FATTY ACID REDUCES NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN HIGH-RISK PATIENTS TREATED WITH A STATIN AND RESIDUAL HYPERTRIGLYCERIDEMIA (ESPRIT TRIAL)

2013 ◽  
Vol 61 (10) ◽  
pp. E1468 ◽  
Author(s):  
Kevin C. Maki ◽  
David Orloff ◽  
Stephen Nicholls ◽  
Richard Dunbar ◽  
Eli Roth ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Free Fatty Acid ◽  
High Risk ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Omega 3 ◽  
Risk Patients

Combined Detection of Free Fatty Acid (FFA) and High-Density Lipoprotein Cholesterol (HDL-C) is a Promising Pretreatment Biomarker for Predicting the Overall Prognosis (OS) of Neuroendocrine Tumours (NETs) in the Colorectum: A Case-Control Study.

2021 ◽  
Author(s):  
Bin Zhu ◽  
Dan Wu ◽  
Yuanyuan Yang ◽  
Pingli Yu ◽  
Haobo Huang ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Free Fatty Acid ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Neuroendocrine Tumours ◽  
Tumour Size ◽  
Density Lipoprotein ◽  
High Density ◽  
Apolipoprotein A1 ◽  
Lipoprotein Cholesterol

Abstract Purpose The aim of the study was to evaluate the prognostic value of free fatty acid (FFA) and high-density lipoprotein cholesterol (HDL-C) in predicting colorectal neuroendocrine tumours (NETs). Methods One hundred patients with pathologically diagnosed colorectal NETs in 2011-2017 were enrolled, and the levels of FFA, HDL-C, low-density lipoproteincholesterol (LDL-C), triglycerides (TGs), cholesterol (CHOL), apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) between colorectal NET patients and healthy controls matched by age and sex were compared. In addition, the association of clinicopathological characteristics and follow-up data with FFA and HDL-C was analysed. Results FFA was overexpressed (0.55±0.23 vs. 0.48±0.11, P= 0.006) and HDL-C was underexpressed (1.31±0.41 vs. 1.41±0.29, P=0.046) in colorectal NETs. FFA ≥0.52 mmol/L predicted lymph node metastasis (LNM) (χ2 = 5.964, P=0.015), and HDL-C ≤1.0 mmol/L predicted tumour size ≥2 cm (χ2 = 5.647, P=0.017). No significant association was found between FFA and tumour size (P=0.142) or HDL-C and LNM (P=0.443). FFA ≥0.52 mmol/L (χ2 = 6.016, P=0.014) and HDL-C ≤1.0 mmol/L predicted worse overall survival (OS) (χ2 = 5.488, P=0.019). FFA ≥0.52 mmol/L in combination with HDL-C ≤1.0 mmol/L predicted an even worse prognosis in terms of OS (χ2 = 4.818, P=0.028). Conclusion FFA ≥0.52 mmol/L and HDL-C ≤1.0 mmol/L were promising cut-off values in predicting LNM, tumour size and worse OS in colorectal NETs.

Interaction of exercise training andn-3 fatty acid supplementation on postprandial lipemia

2007 ◽  
Vol 32 (3) ◽  
pp. 473-480 ◽  
Author(s):  
Tom R. Thomas ◽  
Ying Liu ◽  
Melissa A. Linden ◽  
R. Scott Rector
Keyword(s):  
Fatty Acid ◽  
Exercise Training ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Repeated Measures ◽  
Postprandial Lipemia ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Omega 3

The effect of combining omega-3 fatty acid (n-3 FA) supplementation and exercise training treatment on postprandial lipemia (PPL) has not been studied. The purpose of this study was to examine the interaction of n-3 FA and exercise training in attenuating PPL after a high-fat meal. Previously sedentary, overweight, subjects (n = 22; 12 women, 10 men, BMI 26.6 ±0.7 kg/m2) were randomly assigned to one of two treatment groups: n-3 FA supplementation alone (FO, n = 10) or n-3 FA supplementation plus exercise training (FO+ExTr, n = 12). Both groups consumed 4 g/d n-3 FA, and one group also exercise trained for 45 min/d, 5d/week of brisk walking and (or) jogging at 60% VO2 max. Before and after 4 weeks of treatment, subjects performed a baseline PPL and a PPL following a single session of exercise (ExPPL). PPL was assessed by triglyceride (TG) area under the curve (AUC) and peak TG response (TGpeak). A two-way analysis of variance (ANOVA) with repeated measures was used to compare results from treatments for baseline and exercise trials. FO alone reduced PPL and Ex PPL, and FO+ExTr attenuated the ExPPL response measured as total AUC and TGpeak. There was no significant main effect for group or group by time interaction for baseline PPL or ExPPL. Fasting high-density lipoprotein cholesterol (HDL-C) and HDL2-C (i.e., subfraction 2) concentrations were significantly increased in the FO+ExTr group after the treatments. These results suggest that n-3 FA supplementation reduced PPL in sedentary subjects. Exercise training has no interference or additive effects with n-3 FA supplementation in attenuating PPL, but combined treatments may be additive in raising high-density lipoprotein cholesterol.

Abstract 16133: High Density Lipoprotein Cholesterol is an Alternative Marker to Troponin for Acute Coronary Syndrome in High Risk Patients

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Anke Nguyen ◽  
Heath Adams ◽  
Natalie Yap ◽  
Julian Gin ◽  
Andrew M Wilson
Keyword(s):  
High Risk ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Density Lipoprotein ◽  
Cardiac Troponin I ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Risk Patients

Introduction: It is well known that high density lipoprotein cholesterol is inversely correlated with the risk of coronary artery disease. However, data is limited regarding the relationship of high density lipoprotein cholesterol in the acute setting of coronary artery disease and particularly how it compares to the most well-known biomarker, cardiac troponin I. Hypothesis: We assessed the hypothesis that high density lipoprotein cholesterol could be used as an alternative marker to troponin for acute coronary syndrome (ACS) in high risk patients. Methods: We analysed 740 patients of the BRAVEHEART cohort presenting for coronary angiography at our institution between October 2009 and March 2014. Of these, 153 patients presented with ACS, including 44 with ST elevation myocardial infarction and 109 with non-ST elevation myocardial infarction, and 587 patients presented without ACS. Binary logistic regression was used to compare high density lipoprotein cholesterol and cardiac troponin I levels as predictors of ACS, independent of age, sex, cardiac risk factors and statin use. Results: Patients presenting with ACS had higher median cardiac troponin I levels (0.34 vs. 0.02 μg/L; p<0.001), higher median serum triglyceride levels (1.5 vs. 1.3 mmol/L, p<0.001) and lower median high density lipoprotein cholesterol levels (0.97 vs. 1.09 mmol/L, p<0.001) than patients without ACS. There was no difference in total cholesterol and low density lipoprotein cholesterol between the two groups. After adjusting for differences in patient variables, the strongest independent predictors of ACS were cardiac troponin I (odds ratio (OR), 1.50; 95% confidence interval (CI), 1.24-1.82; p<0.001) and high density lipoprotein cholesterol (OR, 0.12; 95% CI, 0.04-0.36; p<0.001). Conclusion: In conclusion, high density lipoprotein cholesterol was found to be an independent marker of ACS in high risk patients at our institution. Further studies on high density lipoprotein cholesterol could determine its clinical use in conjunction with troponin levels in patients presenting with ACS.

scholarly journals Patterns and trends of potentially inappropriate high-density lipoprotein cholesterol testing in Australian adults at high risk of cardiovascular disease from 2008 to 2014: analysis of linked individual patient data from the Australian Medicare Benefits Schedule and Pharmaceutical Benefits Scheme

BMJ Open ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. e019041 ◽  
Author(s):  
Farshid Hajati ◽  
Evan Atlantis ◽  
Katy J L Bell ◽  
Federico Girosi
Keyword(s):  
Cardiovascular Disease ◽  
High Risk ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Lipid Lowering ◽  
National Guidelines ◽  
Pharmaceutical Benefits Scheme

ObjectivesWe examine the extent to which the adult Australian population on lipid-lowering medications receives the level of high-density lipoprotein cholesterol (HDL-C) testing recommended by national guidelines.DataWe analysed records from 7 years (2008–2014) of the 10% publicly available sample of deidentified, individual level, linked Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) electronic databases of Australia.MethodsThe PBS data were used to identify individuals on stable prescriptions of lipid-lowering treatment. The MBS data were used to estimate the annual frequency of HDL-C testing. We developed a methodology to address the issue of ‘episode coning’ in the MBS data, which causes an undercounting of pathology tests. We used a published figure on the proportion of unreported HDL-C tests to correct for the undercounting and estimate the probability that an HDL-C test was performed. We judged appropriateness of testing frequency by comparing the HDL-C testing rate to guidelines’ recommendations of annual testing for people at high risk for cardiovascular disease.ResultsWe estimated that approximately 49% of the population on stable lipid-lowering treatment did not receive any HDL-C test in a given year. We also found that approximately 19% of the same population received two or more HDL-C tests within the year. These levels of underutilisation and overutilisation have been changing at an average rate of 2% and −4% a year, respectively, since 2009. The yearly expenditure associated with test overutilisation was approximately $A4.3 million during the study period, while the cost averted because of test underutilisation was approximately $A11.3 million a year.ConclusionsWe found that approximately half of Australians on stable lipid-lowering treatment may be having fewer HDL-C testing than recommended by national guidelines, while nearly one-fifth are having more tests than recommended.

Relative Efficacy of Antilipemic Agents in Non–High-Density Lipoprotein Cholesterol Reduction

2012 ◽  
Vol 25 (4) ◽  
pp. 447-456
Author(s):  
Jennifer Santee ◽  
Cameron Lindsey ◽  
Heather Pace
Keyword(s):  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Information Service ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Percentage Reduction ◽  
Omega 3 ◽  
Reductase Inhibitors ◽  
Reported Data

The investigators sought to summarize the percentage reduction in non–high-density lipoprotein cholesterol (non-HDL-C) achieved with various antilipemic regimens and to determine whether certain antilipemic regimens have been proven more effective in lowering non-HDL-C. A search of MEDLINE, International Pharmaceutical Abstracts, and Iowa Drug Information Service Database from 1970 to May 2011 was performed. Criteria were used to exclude studies not published in English, studies with methodology limitations, and studies with variables that may affect efficacy beyond the antilipemic agent administered. Only randomized, controlled trials comparing medications approved by the Food and Drug Administration were reviewed to determine whether significant differences in percentage reduction in non-HDL-C had been observed between different medication regimens. A total of 51 trials reported data that could be used to determine the range of percentage reduction in non-HDL-C achieved by select antilipemic regimens. Of these 51 trials, 38 provided head-to-head comparisons of antilipemic regimens. Rosuvastatin and atorvastatin are the most potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) in lowering non-HDL-C. Adding ezetimibe, fibric acid derivatives, and omega-3 fatty acids to antilipemic monotherapy may result in further reduction in non-HDL-C. Subjects with certain characteristics (eg, nonwhite) were not prevalent in these studies.

Sign in / Sign up

Export Citation Format

Share Document